Alphadopa

📦 Elke bestelling is gedekt door onze Reshipment Assurance Policy — als uw pakket niet binnen 20 werkdagen arriveert, sturen wij het opnieuw.

Waarom bestellen bij MedsBase

Onze generieke medicijnen zijn afkomstig van WHO-GMP gecertificeerde fabrikanten en worden wereldwijd verzonden in discrete, eenvoudige verpakkingen — geen medicijnnaam op de buitenkant van het pakket. Betalingen met kaart worden verwerkt via een gereguleerde processor (betalingsoverzichten vermelden een gereguleerde kaartbetalingprocessor — nooit “MedsBase” of een medicijnnaam). Crypto en SEPA bankoverschrijvingen worden ook geaccepteerd. Elke bestelling wordt ondersteund door ons Reshipment Assurance Policy.

What Is Alphadopa?

Alphadopa is an oral 250 mg Methyldopa tablet from Lupin, supplied in 30-90 tablets. Methyldopa was introduced by Merck Sharp & Dohme in 1960 as Aldomet. Originally developed as an experimental DOPA-decarboxylase inhibitor, its antihypertensive effect in clinical trials led to its launch as one of the first evidence-based HTN drugs. The VA Cooperative Study on Antihypertensive Agents (1967) validated methyldopa-based therapy as the first-ever proof that treating hypertension reduces cardiovascular events — a historic result. Modern use has narrowed dramatically with the arrival of ACEi, ARB, CCB, and beta-blocker classes, but methyldopa remains the gold standard for hypertension in pregnancy, where 40 years of safety data give it a unique position.

How Methyldopa Works

Methyldopa acts on central alpha-2 adrenergic receptors in the brainstem — acts through the false-neurotransmitter metabolite alpha-methyl-noradrenaline, which is stored in adrenergic neurones and released in place of noradrenaline, preferentially stimulating inhibitory alpha-2 receptors and reducing central sympathetic outflow. The downstream effects:

• Conversion to alpha-methyl-noradrenaline in central adrenergic neurones — methyldopa is taken up into the same neurones as endogenous dopa, decarboxylated by the same enzymes, and stored as a “false neurotransmitter”
• Preferential stimulation of inhibitory alpha-2 receptors — the false transmitter is released by nerve activity but preferentially stimulates inhibitory alpha-2 autoreceptors, suppressing further noradrenaline release
• Reduced peripheral sympathetic outflow — smooth, sustained BP reduction; minimal reflex tachycardia because the central sympathetic signal is genuinely reduced rather than simply counterbalanced
• No direct vascular, renal, or cardiac action — the entire clinical effect is central
• No effect on renin-angiotensin system, electrolytes, or glucose — the main reason for its acceptable metabolic profile in pregnancy
• Placental transfer is limited — methyldopa crosses the placenta but produces no measurable fetal or neonatal BP effect in 40 years of pregnancy use

Approved and Evidence-Based Uses

• Hypertension in pregnancy (gold standard, first-line), resistant hypertension as add-on, historical antihypertensive
• Hypertension in pregnancy — first-line per NICE, ACOG, and ISSHP; gold standard
• Resistant hypertension outside pregnancy — fourth/fifth-line add-on
• Historical first-line antihypertensive (VA Cooperative Study 1967) — displaced by better-tolerated modern classes

Pivotal trial evidence: VA Cooperative Study (1967, 1970) — methyldopa + hydrochlorothiazide + reserpine reduced fatal and nonfatal cardiovascular events in hypertensive men. The first and definitive evidence that treating hypertension saves lives. Redman et al. (1976, 1982) — methyldopa in pregnancy did not adversely affect offspring neurodevelopment over 7.5-year follow-up. CHIPS trial (2015) — tighter vs less-tight BP control in pregnancy; methyldopa and labetalol were the most commonly used agents; tighter control reduced severe maternal hypertension without worsening fetal outcomes. NICE / ACOG / ISSHP guidelines consistently list methyldopa, labetalol, and nifedipine as first-line in pregnancy hypertension.

Alphadopa Dosage

Primary dose: Pregnancy hypertension: start 250 mg two or three times daily; titrate every 2-3 days to 500-2,000 mg/day in two to four divided doses (typical maintenance 500 mg TDS to 750 mg TDS). Target office BP <140/90. Preferred because of the largest safety database in pregnancy of any antihypertensive (40+ years, thousands of pregnancies, no teratogenicity or adverse neonatal signal). Non-pregnant adults with resistant HTN: 250 mg two to four times daily, titrating to 2,000 mg/day. Rarely first-line outside pregnancy given better-tolerated modern alternatives.

Other indications: Methyldopa is used almost exclusively for hypertension — especially in pregnancy. Historically used in hypertensive encephalopathy and phaeochromocytoma preparation (now superseded).

Administration: take with or without food; divide daily dose over 2-4 administrations. Evening dose can be largest to shift sedation into sleep.

Monitoring schedule:

• Baseline: supine and standing BP (document postural drop), heart rate, LFTs, full blood count, direct Coombs test, medication list (check for interacting agents).
• Week 1-2: repeat BP (supine and standing), heart rate, symptom review. Adjust dose up or down based on BP and tolerability.
• Week 4-6: assess target BP; symptom burden; repeat LFTs.
• Ongoing: LFTs every 6 months; FBC/Coombs annually. Screen for depression at each visit.
• Stop or dose-reduce on: transaminase rise >3× ULN, unexplained anaemia, severe depression, hypersensitivity reaction.

Discontinuation: no rebound syndrome. Methyldopa can be stopped abruptly when switching regimens, though gradual cross-titration is prudent if the replacement agent takes days to reach steady state.

Practical Considerations for Alphadopa

• Pregnancy gold standard. No reassuringly-large database for any other antihypertensive in pregnancy comes close — this is the principal reason to keep methyldopa in the modern formulary. Alternatives in pregnancy: labetalol, nifedipine, hydralazine.
• Hepatitis risk — idiosyncratic hepatitis and rare fatal fulminant hepatic failure (approximately 1/5,000 exposures). Check LFTs at baseline, then at weeks 4, 8, and 12, then every 6 months. Stop immediately on transaminase rise >3× upper limit of normal or symptoms of hepatitis.
• Coombs-positive haemolytic anaemia — up to 20% of patients develop a positive direct Coombs test after 6-12 months; true haemolytic anaemia is rare (<1%). Check Hb and Coombs at baseline and annually; stop on any unexplained anaemia.
• Sedation and depression — central sympathetic suppression causes significant fatigue, especially at initiation. Avoid in patients with a history of major depression.
• No rebound HTN on discontinuation — contrast with clonidine; methyldopa can be stopped abruptly.
• Interferes with catecholamine assays — methyldopa metabolites can cause false-positive urinary catecholamine results; stop for 7-14 days before phaeochromocytoma testing.

Bijwerkingen

Common (>1%):

• Sedation, fatigue, daytime drowsiness (very common, especially first 2-4 weeks)
• Droge mond
• Orthostatic hypotension, dizziness
• Depression, mood change, reduced libido
• Neusverstopping
• Extrapyramidal symptoms (parkinsonism, bradykinesia) in susceptible patients
• Fluid retention and weight gain
• Positive direct Coombs test (10-20%); rarely progresses to haemolytic anaemia
• Hepatitis (idiosyncratic)
• Fever, hypersensitivity rash

Uncommon but clinically important:

• Idiosyncratic hepatitis, including fulminant hepatic failure — rare but fatal if missed. Monitor LFTs at baseline, 4 weeks, 8 weeks, 12 weeks, then every 6 months.
• Coombs-positive haemolytic anaemia — up to 20% become Coombs-positive, <1% develop frank haemolysis. Check FBC annually or on unexplained fatigue.
• Drug-induced lupus, pancreatitis, myocarditis — rare hypersensitivity.
• Severe depression or suicidal ideation — central sympathetic suppression can deepen depression.
• Bradycardia and heart block (less than clonidine, but possible).
• Extrapyramidal syndromes (parkinsonism) in susceptible patients.

Contra-indicaties

• Active hepatitis or prior methyldopa-related hepatic injury
• Phaeochromocytoma (falsifies catecholamine assays; unopposed alpha-1 activity can paradoxically raise BP)
• MAOI therapy (interaction on sympathetic tone)
• Severe depression
• Haemolytic anaemia of any cause (relative)
• Known hypersensitivity to methyldopa

Pregnancy: first-line antihypertensive in pregnancy. 40+ years of safety data across thousands of pregnancies show no teratogenicity and no adverse neurodevelopmental signal on offspring followed to age 7.5 years (Redman et al.). Dose 250-750 mg twice or three times daily; target BP <140/90. Alternatives: labetalol, nifedipine.

Breastfeeding: compatible with breastfeeding; small amounts in breast milk with no reported adverse effects on the nursing infant.

Geneesmiddelinteracties

• Lithium — methyldopa can increase lithium toxicity at unchanged lithium doses; monitor levels.
• Iron (ferrous sulfate, ferrous gluconate) — reduces methyldopa absorption by 50-80%. Separate doses by at least 2 hours.
• MAO inhibitors — hypertensive crisis via unopposed catecholamine release. Contraindicated combination.
• Levodopa — methyldopa competes with levodopa; reduces anti-parkinsonian effect.
• Tolbutamide, haloperidol, lithium — increased CNS depression.
• Tricyclic antidepressants and sympathomimetics (pseudoephedrine) — antagonise methyldopa’s antihypertensive effect.
• General anaesthetics — additive hypotension; inform anaesthetist.
• Alcohol — additive sedation and orthostatic hypotension.

Where Alphadopa Fits in the Antihypertensive Hierarchy

Opslag

Store Alphadopa below 25°C in the original blister pack. Keep out of reach of children.

Veelgestelde vragen

Is Alphadopa the right drug for high blood pressure in pregnancy?

Yes — methyldopa is the gold-standard antihypertensive in pregnancy and is recommended first-line by NICE, ACOG, and ISSHP guidelines. The reason is not superior BP effect but the unmatched safety database: 40+ years of use across tens of thousands of pregnancies with no teratogenicity or adverse neurodevelopmental signal (Redman follow-up to age 7.5 years). Labetalol and nifedipine are the usual alternatives when methyldopa is not tolerated, and are increasingly used as co-equal first-line choices in modern practice.

Do I need blood tests while on Alphadopa?

Yes — unlike most antihypertensives, methyldopa requires periodic liver and blood-count monitoring because of two rare but serious idiosyncratic reactions: drug-induced hepatitis (roughly 1/5,000) and Coombs-positive haemolytic anaemia (up to 20% positive Coombs, <1% frank haemolysis). Schedule: LFTs at baseline, 4 weeks, 8 weeks, 12 weeks, then every 6 months. Full blood count and direct Coombs at baseline and annually, or sooner on unexplained fatigue or jaundice. Stop methyldopa immediately if transaminases rise above three times the upper limit of normal or if unexplained anaemia develops.

Can I take Alphadopa with alcohol?

Light, occasional drinking is usually tolerated. Regular or heavy drinking substantially potentiates the orthostatic hypotension and sedation of Alphadopa — falls, blackouts, and accidents become more likely. Patients at higher risk (elderly, previous falls, concurrent diuretics or sedatives) should avoid alcohol altogether on this medication.

Why do I feel so tired on Alphadopa?

Methyldopa suppresses central sympathetic drive — the same mechanism that lowers blood pressure reduces overall arousal. Sedation and fatigue are nearly universal in the first 2-4 weeks and usually partially improve by week 6-8. Strategies: shift more of the daily dose to bedtime; avoid alcohol and other CNS depressants; take the smallest effective dose. If fatigue remains disabling after 8-10 weeks, switch to an alternative (labetalol if not pregnant; nifedipine; or an ACE inhibitor if not pregnant). Severe or worsening low mood during methyldopa warrants immediate review — methyldopa can precipitate depression in susceptible patients.

Wat als ik een dosis vergeet?

Take it as soon as you remember, unless it is nearly time for your next dose — in that case skip the missed dose and resume at the next scheduled time. Do not double up. A single missed dose does not materially affect long-term BP control.

Can I stop Alphadopa if my BP is under control?

Methyldopa can be stopped without a rebound syndrome, but hypertension will usually re-emerge within days — chronic HTN is not “cured” by successful treatment. If stopping methyldopa because of side effects, switch to an alternative agent rather than simply discontinuing. Post-partum patients who started methyldopa for gestational hypertension can transition to a modern agent (ACEi, ARB, CCB) if breastfeeding allows; discuss with your specialist.

Can I take Alphadopa in pregnancy?

Yes — methyldopa is the preferred antihypertensive in pregnancy. Alternatives are labetalol and nifedipine. Avoid ACE inhibitors, ARBs, renin inhibitors, and mineralocorticoid receptor antagonists in pregnancy.

Where can I buy Alphadopa online?

You can buy Alphadopa (250 mg methyldopa, 30-90 tablets) from MedsBase with discreet packaging and worldwide shipping.

Related Antihypertensives on MedsBase

• Aldactone — Spironolactone 25/50/100 mg (PATHWAY-2 4th-line)
• Arkamin — Clonidine 100 mcg (Torrent)
• Natrilix SR — Indapamide 1.5 mg (thiazide-like)
• Prazopill XL — Prazosin ER 5 mg
• Ramcor — Ramipril 2.5/5/10 mg (ACEi)
• Telma H — Telmisartan + HCTZ combination
• Browse all High Blood Pressure Medications

Meer opties in medicatie tegen hoge bloeddruk

Gerangschikt op recente bestelvolumes van MedsBase — wat andere klanten in deze categorie kiezen.

Telmaheal

US$9.00 – US$36.00Rango de precios: desde US$9.00 hasta US$36.00

Losar

US$6.53 – US$29.25Rango de precios: desde US$6.53 hasta US$29.25

Amlode

US$5.50 – US$24.00Rango de precios: desde US$5.50 hasta US$24.00

Minoxytop

US$22.00 – US$170.00Rango de precios: desde US$22.00 hasta US$170.00